Consensus on Current Landscape and Treatment Trends of Obesity in India for Primary Care Physicians
Abstract
Conflict of Interest Statement
The authors declare no conflict of interest.
The authors declare no conflict of interest.
What this means for Indian patients
This source is India-specific. It directly reflects the clinical landscape, patient demographics, and guideline context that apply to Indian patients considering GLP-1 therapy. The findings are part of the evidence base GLP-1 Check uses for Indian-guideline-based eligibility assessment — meaning if you are an Indian patient, the conclusions here apply to you with minimal extrapolation.
Apply this evidence
GLP-1 therapy by condition →
PCOS, T2D, NAFLD, hypertension, sleep apnea — Indian guideline framing
India semaglutide brands →
All 12 DCGI-approved brands, prices from ₹220
India 2026 pricing →
Brand-by-brand India price breakdown
GLP-1 brand comparisons →
Ozempic vs Wegovy, Mounjaro vs Wegovy, and more
Free Indian-guideline eligibility check →
5 minutes · Indian BMI thresholds · instant result
Related Sources
GLP-1 Receptor Agonists: Cardiovascular, Mortality, and Kidney Outcomes — Systematic Review and Meta-Analysis (Lancet 2021)
Clinical TrialSELECT Trial — Semaglutide 2.4 mg Cuts CV Events 20% (NEJM 2023)
Clinical TrialSTEP UP Trial: Semaglutide 7.2mg Achieves 20.7% Mean Weight Loss Over 72 Weeks
2026
Check if this evidence applies to you
Take the free 5-minute triage to get your GLP-1 Readiness Score.
Check My Eligibility →